AtaiBeckley Inc

ATAI

Market cap $1.47B

Johnson & Johnson (NYSE:JNJ)'s Spravato is reinforcing investor interest in the broader psychedelics sector as it reported another quarter of strong sales growth, with Jefferies analysts pointing to implications for companies such as AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) and peers developing next-generation mental health treatments. Spravato (esketamine nasal spray), which is approved for treatment-resistant depression (TRD), generated $468 million in global sales in the first quarter of 2026, representing a 46% increase year over year.

Dr. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13 - 16) and the Needham Virtual Psychedelics Forum (April 27) Dr. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13 - 16) and the Needham Virtual Psychedelics Forum (April 27)

AtaiBeckley maintains a "Buy" rating, driven by key pipeline advances in psychedelic-based treatments for treatment-resistant depression. The company's BPL-003 achieved robust, rapid, and statistically significant reductions in MADRS scores in phase 2b, supporting upcoming parallel phase 3 ReConnection studies. The company secured FDA alignment for two pivotal phase 3 trials, with first patient dosing targeted for Q2 2026 and topline data expected in 2029.

The company reported a 66.7% antidepressant response rate at Day 2, which has contributed to the stock's upward momentum as broader markets experienced gains on Tuesday.

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that patients in a mid-stage trial of its experimental depression treatment BPL-003 showed improvement within two days of a single dose, with effects lasting up to 12 weeks. The Phase 2a study found that 66.7% of participants achieved a clinically significant reduction in symptoms by Day 2.

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced peer-reviewed Phase 2a results (NCT05660642) in CNS Drugs demonstrating that a single intranasal dose of BPL-003 (mebufotenin benzoate), which holds FDA Breakthrough Therapy Designation, achieved rapid and sustained reductions in MADRS scores from baseline in participants with treatment-resistant depression (TRD) who remained on stable SSRI therapy throughout the study (n=12). A 66.7% antidepressant response rate (≥50% reduction from baseline MADRS score) was observed at Day 2 in both the 10 mg (n=6) and 12 mg (n=6) cohorts, with 83% (5/6) of participants in the 10 mg cohort and 66.7% (4/6) of participants in the 12 mg cohort maintaining a response at Week 12. BPL-003 was generally well tolerated with no serious adverse events reported, and participants achieved a mean discharge approximately 100 minutes post-dose. Phase 3 studies are on track to initiate in Q2 2026 following recent FDA End-of-Phase 2 (EOP2) alignment.

Deutsche Bank has initiated coverage on AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) assigning a 'Buy' rating and setting a price target of $12, implying potential upside of around 320% from current levels. In a note to clients, analysts highlighted the company's position in the emerging field of psychedelic medicine for mental health.

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that it has been added to a series of major US equity benchmark indices, a move that is expected to increase its visibility among institutional investors and trigger buying from passive investment funds. The clinical-stage biotechnology company announced that it joined the S&P Total Market Index, the S&P Completion Index and CRSP US benchmark indices, effective March 23, 2026.

Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world's largest mutual fund Expands market presence across the S&P Total Market Index, covering virtually all U.S.-listed equities, and the S&P Completion Index, which represents approximately 3,000 mid-, small-, and micro-cap companies not included in the S&P 500® Continues a series of index inclusions across the U.S. equity benchmark landscape, reflecting AtaiBeckley's enhanced eligibility following its U.S. re-domiciliation and building on its addition to the Nasdaq Biotechnology Index in December 2025 NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its addition to the S&P Total Market Index, the S&P Completion Index and CRSP® U.S. benchmark indices, effective March 23, 2026. BPL-003 Phase 3 program remains on track to initiate in Q2 2026, and topline data from the VLS-01 Phase 2b study are expected in H2 2026.

AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. BPL-003 posted encouraging depression data and has the FDA's Breakthrough Therapy Designation. We also know BPL-003 is expected to enter Phase 3 in Q2 2026. VLS-01 and EMP-01 add pipeline depth.